arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cellectar Biosciences, Inc.

CLRB
$2.50 ▲ +0.02 (+0.81%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cellectar Biosciences, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $10.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -137.2%
FCF / Share $-1.14
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.65M
↑ +14.4%
FCF / Share Free cash flow per share
$-1.14
↑ +81.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 24 years · 74 quarters